Health Care / Biotechnology

REGN stock hub

REGN trades against a final fair-value range of $917.25-$1,505.07, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

Read full analysis Valuation Archive

Fair value midpoint

$1210

$917 - $1505

Upside to midpoint

+69.2%

Based on latest report

Confidence

88/100

Data quality and model convergence

Market cap

$74.9B

NASDAQ

Our take

Research highlights

What our analysis says

Pulled from the latest published report. The full reasoning lives under /analysis.

Biggest opportunity

Bull case

Bull: Dupixent dominates the immunology space longer than anticipated, and high-dose Eylea proves impenetrable to biosimilar erosion. Operating leverage drives margins past 35%, yielding an intrinsic value of $1,505.

Biggest risk

High-Dose Eylea Fails to Defend Share

Recommended action

Strong Buy

REGN is rated Strong Buy at $714.89 versus the reconciled fair value midpoint of $1,209.72, implying +69.22% upside/downside. Confidence is separately disclosed at 88/100.

Market data

Live price

Polled client-side every 30 s; the bare-URL shell stays cacheable for a full day.

Current price

REGN

Source: backend price pulse endpoint

In the news

Latest headlines

Fetched client-side; each row carries the publisher and the read-out date.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Fetched client-side from the daily earnings-calendar mirror.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Analysis map

Jump into the research surface

These links all point into /analysis/*, so a hub rollback leaves the report reader and legacy redirects live.

Forecast

Targets

Bull, base, and bear cases with expected-return framing.

Valuation

Models

Fair-value bridge, DCF, owner earnings, and peer multiples.

Sensitivity

Grid

Cost-of-equity and terminal-growth stress table.

Risks

Bear case

Kill scenarios, soft-pass flags, and downside catalysts.

Earnings

Decision tree

Next earnings setup and beat / inline / miss thresholds.

Position sizing

Checkpoints

Entry, exit, conviction, and quarterly monitoring rules.

Financials

History

Revenue, margins, cash flow, and balance-sheet context.

Peers

Comps

Relative valuation and profitability against the cohort.

Moat

Durability

Economic-profit evidence and competitive advantage risk.

Industry cycle

Context

Sector phase, capital cycle, and secular tailwinds.

Scorecard

Factors

Six-factor overlay and 9-category weighted scorecard.

Recommendation

Verdict

Final action, action steps, opportunity, and biggest risk.

Perspectives

Lenses

Growth, value, and income investor reads.

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E13.3

P25 n/aP50 n/aP75 n/a

Trailing P/E0

P25 n/aP50 n/aP75 n/a

ROE14.5

P25 n/aP50 n/aP75 n/a

ROIC12.9

P25 n/aP50 n/aP75 n/a

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Our take

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

9/10

Business quality stays separate from stock attractiveness.

Forward P/E

13.3x

Valuation uses the full report model stack, not a single multiple.

Next action

Strong Buy

Final action steps are kept in the recommendation tab.

Our take

Income

REGN dividend yield, growth & safety

Yield, payout sustainability, and the multi-year growth streak.

Dividend yield

+0.5%

$3.76 annual per share

Payout ratio

+8.9%

Share of earnings returned as dividends. Below 60% is generally sustainable.

5Y dividend CAGR

n/a

1 consecutive years of growth

Total shareholder yield

+6.1%

Next ex-dividend date: 2026-05-20

Performance

REGN stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns REGN?

Insider, institutional, and short-interest positioning.

Institutional ownership

+89.5%

Float: +96.0% of shares outstanding

Insider ownership

+3.8%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

REGN momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

43.9

Neutral momentum band

Price vs 200-day MA

+4.0%

50/200-day relationship not available

Beta (5Y)

0.30

Less volatile than the market

Sharpe ratio

0.74

Risk-adjusted return — higher is better; >1.0 is solid.

Peers

REGN vs. sector cohort

Currency-neutral comparison: P/E, P/S, ROIC, 5Y revenue CAGR, and 1Y total return. Market-cap column appears only when every peer reports in the same currency.

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	4.3T	35.6x	9.5x	104.3%	+6.8%	+50.1%	Verkaufen
ABNB	Airbnb Inc.	84.1B	34.6x	6.7x	15.9%	+29.9%	+14.9%	Halten
ADBE	Adobe Inc.	102.3B	14.8x	4.2x	63.3%	+12.3%	-34.3%	Starker Kauf
ABBV	AbbVie Inc.	356.5B	99.3x	5.7x	22.2%	+4.6%	+10.6%	Halten
ABT	Abbott Laboratories	146.9B	23.6x	3.3x	9.6%	+3.9%	-35.8%	Starker Kauf
AMGN	Amgen Inc.	179B	23.1x	4.8x	19.1%	+8.1%	+24.0%	Starker Kauf

Questions

About REGN

Hub-level FAQ points readers to the deeper analysis pages.

What is the current REGN stock rating?

Regeneron Pharmaceuticals Inc. is currently shown with Strong Buy in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full REGN analysis?

The full report lives at /stocks/REGN/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for REGN?

The latest report frames REGN around $917 to $1505. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the REGN page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.

Canonical hub: /de/stocks/REGN. Analysis surface: /de/stocks/REGN/analysis.